Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...

Decreased AChR-Ab titers correlated with improved myasthenia gravis symptoms, especially in ADL scores, within the first 3 months of treatment. The study found no baseline correlation between AChR ...

I'm Dr. John Whyte, the Chief Medical Officer of WebMD. Today, I want to talk about a serious autoimmune condition called myasthenia gravis. It comes from the Latin and Greek which means grave ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor ...

For example, disrupted ion channel or neurotransmitter receptor distribution or density play important roles in neuropathic pain, spinal cord injury, schizophrenia, myasthenia gravis, epilepsy, and ...

Areas of particular research interest are Motor Neuron Disease, Muscular Dystrophy, Inflammatory Myopathy (Myositis), Myasthenia Gravis and stem cell therapy.

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...